Clinical Trials at NIH: Clinical Research: Search for Clinical Trials at NIH

The National Cancer Institute (NCI) conducts more than 150 cancer clinical trials at the National Institutes of Health (NIH) Clinical Center in Bethesda, Maryland. Cancer clinical trials that take place at the NIH Clinical Center are open to patients with cancer, regardless of where they live in the United States.

Go to Search Page

There are 38 clinical trials at NIH that match your search criteria

Cancer by type: Lymphoma

Trial and Protocol Number Lymphoma	Principal Investigator	Referral Contact
Phase II
Phase II Study of UCN-01 in Relapsed or Refractory Systemic Anaplastic Large Cell and Mature T-Cell Lymphomas NCI-04-C-0173	Wyndham H. Wilson 301-435-2415	Peggy Shovlin 301-594-6597 mshovlin@mail.nih.gov

Trial and Protocol Number Lymphoma (Adult)	Principal Investigator	Referral Contact
Phase III
Phase III Randomized Study of R-CHOP Versus Dose-Adjusted EPOCH-R With Molecular Profiling in Untreated De Novo Diffuse Large B-Cell Lymphomas NCI-05-C-0252	Wyndham H. Wilson 301-435-2415	Peggy Shovlin 301-594-6597 mshovlin@mail.nih.gov
Phase II
A Phase II, Multicenter, Open-Label Trial Evaluating the Activity and Tolerability of Romidepsin (Depsipeptide, FK228) in Progressive or Relapsed Peripheral T-Cell Lymphoma Following Prior Systemic Therapy NCI-08-C-0164	Richard Piekarz 301-402-3524	Robin Frye 301-402-5958 fryer@mail.nih.gov
Randomized Phase II Study of Dose-Adjusted EPOCH-Rituximab-Bortezomib Induction Followed by Bortezomib Maintenance Versus Observation in Untreated Mantle Cell Lymphoma With Microarray Profiling and Proteomics NCI-05-C-0170	Wyndham H. Wilson 301-435-2415	Therese White 301-402-5886 whiteth@mail.nih.gov
Pilot Trial of Alemtuzumab and Dose-Adjusted EPOCH in Chemotherapy Naive Aggressive T and NK-Cell Lymphomas NCI-03-C-0304	Wyndham H. Wilson 301-435-2415	Peggy Shovlin 301-594-6597 mshovlin@mail.nih.gov
A Pilot Study of MDX-CTLA-4 in Lymphoma NCI-02-C-0284	John E. Janik 301-402-2913	Guinevere Chun 301-451-7868 gchun@mail.nih.gov
Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Patients With Aggressive Non-Hodgkin’s Lymphoma NCI-93-C-0133 (Multi-center study)	Wyndham H. Wilson 301-435-2415	Therese White 301-402-5886 whiteth@mail.nih.gov
Phase I/II
A Phase I/II Study of Flavopiridol in Relapsed or Refractory Mantle Cell Lymphoma (MCL) and Diffuse Large B-Cell Lymphoma (DLBCL) NCI-07-C-0081	Kieron Dunleavy 301-435-1007	Therese White 301-402-5886 whiteth@mail.nih.gov
A Phase I/IIa Study Evaluating the Safety, Pharmacokinetics, and Efficacy of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies NCI-07-C-0006	Wyndham H. Wilson 301-435-2415	Peggy Shovlin 301-594-6597 mshovlin@mail.nih.gov
Phase I/II Study of Yttrium Y 90 Labeled Humanized Anti-Tac Monoclonal Antibody (Y-HAT) and Pentetic Acid Calcium (Ca-DTPA) in Patients With Tac-Expressing Hematologic Malignancies Other Than Adult T-Cell Leukemia NCI-97-C-0110F	Thomas Waldmann 301-496-6656	Suzanne Fioravanti 301-594-6544 fioravas@mail.nih.gov

Trial and Protocol Number Lymphoma, Cutaneous T-cell (CTCL)	Principal Investigator	Referral Contact
Phase II
A Phase II Clinical Trial of Anti-Tac(Fv)-PE38 (LMB-2) Immunotoxin for Treatment of CD25 Positive Cutaneous T-Cell Lymphomas NCI-04-C-0142	Robert J. Kreitman 301-496-6947	Linda Ellison 301-496-9458 ellisonl@mail.nih.gov
Phase I
Phase I Pilot Study of Topical Romidepsin in Patients With Stage IA, IB, or IIA Cutaneous T-Cell Non-Hodgkin’s Lymphoma NCI-07-C-0133	Maria L. Turner 301-496-7737	Susan Booher 301-402-1474 boohers@mail.nih.gov
No Phase
Pathogenesis and Course of Cutaneous T-Cell Lymphoma NCI-04-C-0081	Sam Hwang 301-496-8724	Susan Booher 301-402-1474 boohers@mail.nih.gov

Trial and Protocol Number Lymphomatoid Granulomatosis	Principal Investigator	Referral Contact
Phase II
Treatment and Natural History Study of Lymphomatoid Granulomatosis NCI-94-C-0074	Wyndham H. Wilson 301-435-2415	Nicole Grant 301-594-2947 grantn@mail.nih.gov

Trial and Protocol Number AIDS Related Cancers	Principal Investigator	Referral Contact
Phase II
AIDS-Related Primary Central Nervous System Lymphoma: A Phase II Pilot Study of High-Dose Intravenous Methotrexate With Rituximab Leucovorin Rescue and Highly Active Antiretroviral Therapy NCI-06-C-0051	Robert Yarchoan 301-496-8959	Karen Aleman 301-496-8959 1-800-243-2732 ext. 4 (Toll Free) alemank@mail.nih.gov
Short-Course EPOCH-Rituximab in Untreated CD-20+ HIV-Associated Lymphomas NCI-01-C-0030	Wyndham H. Wilson 301-435-2415	Nicole Grant 301-594-2947 grantn@mail.nih.gov

Trial and Protocol Number Graft-Versus-Host Disease	Principal Investigator	Referral Contact
No Phase
Prospective Assessment of Clinical and Biological Factors Determining Outcomes in Patients With Chronic Graft-Versus-Host Disease (GVHD) NCI-04-C-0281	Steven Pavletic 301-402-4899	Bazetta (Zetta) Blacklock 301-594-2056 bblacklock@mail.nih.gov

Trial and Protocol Number Hematologic/Blood Cancers	Principal Investigator	Referral Contact
Phase II
Allogeneic HSCT Without Preparative Chemotherapy or With Low-Intensity Preparative Chemotherapy Using Sirolimus and Sirolimus Generated Donor Th2 Cells for Therapy of Refractory Leukemia, Lymphoma, Myeloma, or Myelodysplastic Syndrome NCI-04-C-0055	Daniel Fowler 301-435-8641	Bazetta (Zetta) Blacklock 301-594-2056 bblacklock@mail.nih.gov
Phase I/II
A Pilot Trial of WT1 Peptide-Loaded Allogeneic Dendritic Cell Vaccine and Donor Lymphocyte Infusion for WT1-Expressing Hematologic Malignancies NCI-08-C-0051	Alan Wayne 301-496-4256	Pediatric Oncology 1-877-624-4878 (Toll free)
Pilot Trial of Targeted Immune-Depleting Chemotherapy and Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation Using HLA-Matched Unrelated Donors and Utilizing Two Graft-versus-Host Disease Prophylaxis Regimens for the Treatment of Leukemias, Lymphomas, and Pre-malignant Blood Disorders NCI-07-C-0195	Michael Bishop 301-435-2764	Bazetta (Zetta) Blacklock 301-594-2056 bblacklock@mail.nih.gov
Pilot Study of Non-Myeloablative, HLA-matched Allogeneic Stem Cell Transplantation for Pediatric Hematopoietic Malignancies NCI-01-C-0125	Alan Wayne 301-496-4256	Pediatric Oncology 1-877-624-4878 (Toll free)
Phase I
A Phase I, Multicenter, Dose Escalation Study of CAT-8015 in Children, Adolescents, and Young Adults With Refractory CD22+ Acute Lymphoblastic Leukemia (ALL) or Non-Hodgkin’s Lymphoma (NHL) NCI-08-C-0123	Alan Wayne 301-496-4256	Pediatric Oncology 1-877-624-4878 (Toll free)
Adoptive Cell Therapy for B-Cell Malignancies After Allogeneic Hematopoietic Stem Cell Transplantation With Costimulated, Tumor-Derived Lymphocytes NCI-07-C-0064	Michael Bishop 301-435-2764	Bazetta (Zetta) Blacklock 301-594-2056 bblacklock@mail.nih.gov
Multi-Institutional Phase I Trial of Intravenous Fenretinide (4-HPR) for Patients With Hematologic Malignancies NCI-06-C-0227	Anthony J. Murgo 301-496-4291	Janelle Bingham 301-435-2715 jbingham@mail.nih.gov
T-Cell Depleted, Reduced-Intensity Allogeneic Stem Cell Transplantation From Haploidentical Related Donors for Hematologic Malignancies NCI-04-C-0116	Michael Bishop 301-435-2764	Bazetta (Zetta) Blacklock 301-594-2056 bblacklock@mail.nih.gov
Pediatric Phase I Trial of BL22 for Refractory CD22-Positive Leukemias and Lymphomas NCI-04-C-0079	Alan Wayne 301-496-4256	Pediatric Oncology 1-877-624-4878 (Toll free)

Trial and Protocol Number Leukemia	Principal Investigator	Referral Contact
Phase I/II
Phase I/II Study of the Efficacy and Toxicity of Humanized Anti-Tac (Zenapax®) in the Therapy of Tac-Expressing Adult T-Cell Leukemia NCI-00-C-0030	John C. Morris 301-402-2912	Suzanne Fioravanti 301-594-6544 fioravas@mail.nih.gov

Trial and Protocol Number Leukemia (Adult)	Principal Investigator	Referral Contact
Phase II
Phase II Study of the Efficacy and Toxicity of Ontak® (Denileukin Diftitox) in the Therapy of Adult T-Cell Leukemia NCI-05-C-0185	John E. Janik 301-402-2913	Suzanne Fioravanti 301-594-6544 fioravas@mail.nih.gov
Phase II Study of the Efficacy and Toxicity of CAMPATH-1H in the Therapy of Adult T-Cell Leukemia NCI-03-C-0194	John C. Morris 301-402-2912	Suzanne Fioravanti 301-594-6544 fioravas@mail.nih.gov

Trial and Protocol Number Solid Tumor (Adult)	Principal Investigator	Referral Contact
Phase I
A Phase I Study of ABT-888 in Combination With Metronomic Cyclophosphamide in Adults With Refractory Solid Tumors and Lymphomas NCI-09-C-0048	Shivaani Kummar 301-435-5402	Deborah Allen 301-402-5640 allendeb@mail.nih.gov
A Phase I and Pharmacokinetic Single-Agent Study of Pazopanib in Adults With Advanced Malignancies and Varying Degrees of Liver Dysfunction NCI-09-C-0003	Shivaani Kummar 301-435-5402	Laura D. Otten 301-451-1228 1-866-611-6310 (Toll Free) ottenl@mail.nih.gov
Phase I Study of SNX-5422 Mesylate in Adults With Refractory Solid Tumor Malignancies and Lymphomas NCI-08-C-0091	Giuseppe Giaccone 301-496-4916	Janelle Bingham 301-435-2715 jbingham@mail.nih.gov
Phase I Study of Vandetanib (ZD 6474) and Bevacizumab Combination Therapy Evaluating the VEGF and EGF Signal Transduction Pathways in Adults With Solid Tumors and Lymphomas NCI-08-C-0087	Shivaani Kummar 301-435-5402	Deborah Allen 301-402-5640 allendeb@mail.nih.gov
Phase I Trial of Fenretinide (4-HPR, NSC 374551) Lym-X-Sorb^TM (LXS) Oral Powder (4-HPR/LXS Oral Powder) (4-HPR) in Adults With Solid Tumors and Lymphomas NCI-08-C-0030	Anthony J. Murgo 301-496-4291	Janelle Bingham 301-435-2715 jbingham@mail.nih.gov
Phase I and Pharmacokinetic Study of Vorinostat for Solid Tumors and Lymphomas in Patients With Varying Degrees of Hepatic Dysfunction NCI-07-C-0228	Shivaani Kummar 301-435-5402	Janelle Bingham 301-435-2715 jbingham@mail.nih.gov
A Phase I Study of ABT-888 in Combination With Topotecan Hydrochloride in Adults With Refractory Solid Tumors and Lymphomas NCI-07-C-0203	Shivaani Kummar 301-435-5402	Janelle Bingham 301-435-2715 jbingham@mail.nih.gov

Trial and Protocol Number Solid Tumor (Childhood)	Principal Investigator	Referral Contact
Phase I
A Phase I Study of Ipilimumab (Anti-CTLA-4) in Children, Adolescents, and Young Adults With Treatment Refractory Cancer NCI-08-C-0007	Crystal Mackall 301-402-5940	Pediatric Oncology 1-877-624-4878 (Toll free)
Phase I Trial of Monoclonal Antibody HGS-ETR2 (Lexatumumab) in Patients With Refractory Pediatric Solid Tumors NCI-07-C-0040	Crystal Mackall 301-402-5940	Pediatric Oncology 1-877-624-4878 (Toll free)

If there are no studies listed for your specific disease type, please search under:

Solid Tumor (advanced malignancy)